Thursday, 5 November 2026European Markets

CRCAM SUD R.A.CCI And WENDEL Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - crcam sud r.a.cci (crsu.pa) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
crcam sud r.a.cci (crsu.pa) €111.00 5.25% 3.02%
wendel (mf.pa) €94.60 4.36% 8.19%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. crcam sud r.a.cci (crsu.pa)

5.25% forward dividend yield and 3.02% return on equity

caisse régionale de crédit agricole mutuel sud rhône alpes provides various banking products and services in france. the company provides accounts and credit cards; savings account and term savings; stock market and financial investments; responsible and real estate investment; and retirement services. it offers insurance, such as life, home, car and two-wheeler, health and provident, leisure and daily life, and creditor insurance; and loans, including real estate, consumer, work credits, and vehicle loans. the company was incorporated in 1995 and is based in grenoble, france. caisse régionale de crédit agricole mutuel sud rhône alpes is a subsidiary of crédit agricole s.a.

earnings per share

as for profitability, crcam sud r.a.cci has a trailing twelve months eps of €20.07.

pe ratio

crcam sud r.a.cci has a trailing twelve months price to earnings ratio of 5.53. meaning, the purchaser of the share is investing €5.53 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.02%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, crcam sud r.a.cci's stock is considered to be oversold (<=20).

more news about crcam sud r.a.cci.

2. wendel (mf.pa)

4.36% forward dividend yield and 8.19% return on equity

wendel is a private equity firm specializing in equity financing in middle markets and later stages through leveraged buy-out and transactions and acquisitions. it invests in both listed and non-listed companies. the firm typically invests in technology services and software, business services, healthcare, and industrial technology. the firm seeks to invest in africa, europe, european developed markets, western europe, particularly france, and north america (united states and canada). it invests between €300 million($325.73 million) and €800 million($868.60 million). it targets majority/control/large minority investments in listed or unlisted companies. the firm seeks to take a seat on the board of directors or supervisory board and key committees of its portfolio companies. it makes balance sheet investments. wendel was founded in 1704 and is headquartered in paris, france with additional offices across asia, north america, united kingdom and europe.

earnings per share

as for profitability, wendel has a trailing twelve months eps of €2.03.

pe ratio

wendel has a trailing twelve months price to earnings ratio of 46.6. meaning, the purchaser of the share is investing €46.6 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.19%.

volatility

wendel's last week, last month's, and last quarter's current intraday variation average was 0.35%, 0.24%, and 0.91%.

wendel's highest amplitude of average volatility was 0.90% (last week), 0.65% (last month), and 0.91% (last quarter).

more news about wendel.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com